Docebo Inc. is downgraded to a Sell due to a slowing revenue growth rate, lack of near-term catalysts. Learn more about DCBO ...

Niagen Bioscience posts record Q3 revenue, boosted by Tru Niagen and new partnerships. Read here for an investment analysis of NAGE stock.